Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $25.00. The ...

We came across a bullish thesis on Genmab A/S (GMAB) on Substack by Oliver | MMMT Wealth. In this article, we will summarize ...

Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an analysis of GMAB stock now.

In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry witnessed ...

The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved Tivdak for the treatment of advanced or recurrent ...

Envestnet Portfolio Solutions Inc. reduced its holdings in Genmab A/S (NASDAQ:GMAB – Free Report) by 29.3% in the 4th quarter, according to the company in its most recent 13F filing with the ...

In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other cash-rich undervalued stocks. Currently, big tech and high-growth stocks dominate the stock ...

Assetmark Inc. lowered its position in Genmab A/S (NASDAQ:GMAB – Free Report) by 78.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 18,109 shares of the company’s stock ...

Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform to Outperform. As of January 29, 2025, the average one-year price ...

We came across a bullish thesis on Genmab A/S (GMAB) on Substack by Oliver | MMMT Wealth. In this article, we will summarize the bulls’ thesis on GMAB. Genmab A/S (GMAB)'s share was trading at $ ...